| ACPA-positive RASF | ACPA-negative and ACPA-positive RASF |
---|
ACPA-related biomarkers | Sensitivity | Specificity | Sensitivity | Specificity |
---|
ACPA (CCP2) | N/A | N/A | 85 % | 75 % |
cFbα-peptide (#1) | 94 % | 80 % | 85 % | 95 % |
cFbβ-peptide (#2) | 65 % | 100 % | 55 % | 100 % |
cH2A-peptide (#3) | 70 % | 80 % | 60 % | 95 % |
(#1) + (#2) | 94 % | 80 % | 85 % | 95 % |
(#1) + (#3) | 100 % | 80 % | 90 % | 95 % |
(#2) + (#3) | 88 % | 80 % | 75 % | 95 % |
(#1) + (#2) + (#3) | 100 % | 80 % | 90 % | 95 % |
- Sensitivity in this context is defined as the percentage of NI-0101 responders identified as positive in the assay and specificity as the percentage of NI-0101 non-responders identified as negative in the assay. Sensitivity and specificity were determined in the following groups: (i) anti-citrullinated protein antibodies (ACPA)-positive rheumatoid arthritis synovial fluid (RASF) samples (n = 22), (ii) ACPA-negative and ACPA-positive RASF samples (n = 40). N/A not applicable, CCP2 anti-cyclic citrullinated peptide-2